A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Oncogenes are mutated growth-promoting genes causing excessive proliferation; activation requires only one copy (dominant). Tumor suppressors restrain growth; loss requires inactivation of both copies (recessive). Classic suppressors (TP53, RB, APC) are lost early in carcinogenesis.
Compare gain-of-function (oncogenes) and loss-of-function (suppressors) mutations using examples. Understand Knudson's two-hit hypothesis for tumor suppressors. Study therapeutic implications: oncogenes are actionable targets (EGFR, BCR-ABL).
Not all mutations in oncogenes are cancer-causing—some are passenger mutations with no functional consequence. Heterozygous loss of a tumor suppressor does not cause disease; both alleles must be disrupted.
Normal cell division is controlled by a balance between growth-promoting signals and growth-restraining checkpoints. You know from gene regulation that transcription factors, signal transduction proteins, and cell cycle regulators are encoded by genes that can be altered by mutation. Cancer results not from a single mutation but from the accumulation of mutations that tip this balance—turning up accelerators and disabling brakes simultaneously. Oncogenes are the accelerators; tumor suppressor genes are the brakes. Understanding both classes, and how they differ mechanistically, is the foundation for thinking about cancer genetics.
An oncogene is a mutated or overexpressed version of a normal growth-promoting gene (the normal version is called a proto-oncogene). Proto-oncogenes encode growth factors, growth factor receptors, signal transduction proteins (like RAS), and transcription factors that promote entry into the cell cycle. A mutation that locks one of these proteins in the "on" state creates an oncogene: the cell receives a permanent growth signal without needing external stimulation. Because one mutant copy is sufficient to override the normal copy, oncogene mutations are dominant—like a stuck gas pedal that pushes through even when the other pedal is working normally. Classic examples include *KRAS* mutations (found in roughly 25% of all human cancers), *HER2* amplification (breast cancer), and the *BCR-ABL* translocation in chronic myeloid leukemia that creates a constitutively active kinase.
Tumor suppressor genes work differently: their normal function is to restrain proliferation—halting the cell cycle at checkpoints, repairing DNA damage, or triggering apoptosis when damage is irreparable. Losing a tumor suppressor removes a brake. But because each cell carries two gene copies, both must be inactivated before protective function is lost. This is Knudson's two-hit hypothesis: one inherited or somatic mutation (first hit) plus a second somatic mutation or loss of heterozygosity (second hit) completes the inactivation. The germline-inheritance implication is powerful: individuals born with one mutant copy in every cell—as in Li-Fraumeni syndrome (*TP53*) or familial adenomatous polyposis (*APC*)—need only one additional somatic event per cell to lose function, dramatically accelerating cancer onset. Key tumor suppressors include *TP53* (mutated in over 50% of cancers, coordinates the DNA damage response), *RB1* (a core cell cycle brake at the G1/S checkpoint), and *APC* (restrains proliferative Wnt signaling in intestinal epithelium).
Together, these two gene classes underpin the multi-step model of carcinogenesis: cancer cells typically accumulate both oncogenic activation and tumor suppressor loss over years or decades, explaining why cancer incidence rises steeply with age. The framework also explains why targeted therapies can work: drugs like imatinib (targeting BCR-ABL in CML) exploit a cancer cell's dependence on a specific activated oncogene, selectively killing cells that rely on that signal while sparing normal cells whose growth is governed by intact regulatory systems.